2023-506707-25-00已完成3 期
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 40
研究概览
简要总结
- To evaluate the efficacy of intravitreal (IVT) injections of faricimab compared with ranibizumab
研究设计
- 分配方式
- Randomized
- 主要目的
- Phase Iii,multi Center, Randomized, Double-masked, Active Comparator Controlled Study
- 盲法
- Double (Subject, Investigator)
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Overtly healthy as determined by medical evaluation that includes medical history, physical examination, and laboratory tests
- •Treatment-naïve choroidal neovascularization (CNV) secondary to myopia
- •Diagnosis of active myopic CNV in the study eye confirmed by ocular examination and CRC review
- •BCVA of 78 to 24 letters, inclusive (20/32 to 20/320 approximate Snellen equivalent), using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and assessed at the initial testing distance of 4 meters (see the BCVA manual for additional details) on Day 1
- •Presence of at least 1 of the following lesion types (determined by CRC): Subfoveal (presence of abnormal neovasculature in the avascular central fovea) Juxtafoveal (presence of abnormal neovasculature not under the center of the fovea but ≤ 200 um from the center) with involvement of the central macular area Extrafoveal (presence of abnormal neovasculature > 200 um from the center of the fovea) with involvement of the central macular area Margin of the optic disc (presence of abnormal neovasculature at peripapillary area) with involvement of the central macular area
- •Sufficiently clear ocular media and adequate pupillary dilatation to allow acquisition of good quality retinal images to confirm diagnosis
排除标准
- •CNV due to causes other than pathologic myopia, such as neovascular age-related macular degeneration, ocular histoplasmosis, trauma, angioid streaks, choroidal rupture, or uveitis, etc
- •Any history of macular pathology unrelated to pathologic myopia affecting vision or contributing to the presence of intraretinal or subretinal fluid
- •Presence at screening of central serous chorioretinopathy or myopic tractional maculopathy. Retinal pigment epithelial tear involving the macula on Day 1
- •Non-functioning non-study eye, defined as either: BCVA Snellen equivalent of 20/200 or worse No physical presence of non-study eye (i.e., monocular)
- •Prior IVT administration of faricimab in either eye
- •History of idiopathic or autoimmune-associated uveitis in either eye. Active ocular inflammation (anterior, intermediate or posterior uveitis, grade trace or above) or suspected or active ocular or periocular infection in either eye on Day 1
研究组 & 干预措施
Lucentis 10 mg/ml solution for injection
Comparator
干预措施: Lucentis 10 mg/ml solution for injection (Drug)
FARICIMAB
Test
干预措施: FARICIMAB (Drug)
研究者
Trial Information System - TISL
Scientific
F. Hoffmann-La Roche AG
研究点 (40)
Loading locations...
相似试验
尚未招募
不适用
To Compare Two Different Eye Injections for Premature Babies with Retinal ProblemCTRI/2025/08/092489Janani Shishu Suraksha Karyakram20
尚未招募
Unknown
Intraocular pressure changes after intravitreal Anti-VEGF injection in Retinopathy of PrematurityCTRI/2025/08/093657Maulana Azad Medical College Guru Nanak Eye Centre24
招募中
4 期
A Study to Determine Safety and Long-Term Effectiveness of Faricimab in Participants with Age-Related Macular Degeneration2024-517545-13-00F. Hoffmann-La Roche AG89
尚未招募
3 期
Study to compare the efficacy, safety and immunogenicity of aflibercept intravitreal injection and Eylea (Aflibercept) intravitreal injection in patients with Diabetic Macular Oedema (DME)CTRI/2025/06/089346Intas Pharmaceuticals Limited250
进行中（未招募）
1 期
Intravitreal Adalimumab in Inherited and Degenerative Retinal DiseasesNCT07348588Centro de Pesquisa Rubens Siqueira30